1245 POSTER Phase I Dose-escalation Study of the Oral Selective C-Met Inhibitor EMD 1204831 in Patients With Advanced Solid Tumours von Falchook, G.S, Fu, S, Amin, H.M, Tsimberdiou, A.M, Hong, D.S, Naing, A, Klevesath, M.B, Mattiacci, M.R, Johne, A, Kurzrock, R

Volltext

1246 POSTER A Phase I Dose-escalation Study of EMD 1214063, an Oral Selective C-Met Inhibitor, in Patients With Advanced Solid Tumours von Falchook, G.S, Fu, S, Amin, H.M, Piha-Paul, S.A, Hong, D.S, Naing, A, Klevesath, M.B, Mattiacci, M.R, Di Cara, A, Kurzrock, R

Volltext

Will the first dominant follicle of the estrous cycle of heifers ovulate following luteolysis on day 7? von Savio, J.D., Boland, M.P., Hynes, N., Mattiacci, M.R., Roche, J.F.

Volltext

First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC)... von Paridaens, R, Therasse, P, Dirix, L, Beex, L, Piccart, M.J, Cameron, D, Cufer, T, Roozendael, K, Nooy, M, Mattiacci, M.R

Volltext

Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer. First results of a randomized phase III trial EORTC 10901 von Paridaens, R, Dyczka, J, Rutgers, E.J.T, Coleman, R, Cufer, T, Jassem, J, Nortier, J.W.R, Morales, L, Mattiacci, M.R, Therasse, P

Volltext